Pediatric adverse event review
Executive Summary
FDA's Pediatric Advisory Committee will meet March 25 to discuss adverse event reports for several drugs used in pediatric patients, as mandated by the Best Pharmaceuticals for Children Act. Drugs discussed will include: AstraZeneca's Toprol XL, Baxter's Brevibloc and Suprane, Novartis' Lotensin, GlaxoSmithKline's Coreg, Salix's Colazal, Sanofi-Aventis' Eloxatin and Pfizer's Celebrex...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.